T細胞リンパ腫市場レポート：2030年までの動向、予測、競合分析

T細胞リンパ腫の動向と予測

世界のT細胞リンパ腫市場は、2024年から2030年までのCAGRが6.5％で、2030年までに推定33億米ドルに達すると予想されます。この市場の主な促進要因は、世界のT細胞リンパ腫の罹患率の上昇、がん治療に関する技術の進歩、CAR-T細胞療法や免疫チェックポイント阻害剤を含む免疫療法の使用の増加です。世界のT細胞リンパ腫市場の将来は、放射線療法、化学療法、免疫療法、幹細胞移植の各市場における機会によって有望視されています。

T細胞リンパ腫市場の洞察

Lucintelの予測では、末梢性T細胞リンパ腫が予測期間中に最も高い成長を遂げる見込みです。これは、小児や若年成人に多く見られるようになったためで、成長が遅いタイプのリンパ腫ですが、治療が困難な場合があります。

北米は、T細胞リンパ腫の罹患率が高いこと、主要な業界参入企業が存在すること、研究開発活動が活発であることから、予測期間中も最大地域であり続けると思われます。

本レポートでは、以下の11の主要な質問について回答する：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.今後成長が加速するセグメントとその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のT細胞リンパ腫市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のT細胞リンパ腫市場動向（2018～2023年）と予測（2024～2030年）
• タイプ別の世界のT細胞リンパ腫市場
  • 末梢性T細胞リンパ腫
  • 皮膚T細胞リンパ腫
  • 未分化大細胞リンパ腫
  • 血管免疫芽球性T細胞リンパ腫
• 療法別の世界のT細胞リンパ腫市場
  • 放射線療法
  • 化学療法
  • 免疫療法
  • 幹細胞移植
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界のT細胞リンパ腫市場
• 北米のT細胞リンパ腫市場
• 欧州のT細胞リンパ腫市場
• アジア太平洋のT細胞リンパ腫市場
• その他地域のT細胞リンパ腫市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • タイプ別の世界のT細胞リンパ腫市場の成長機会
  • 療法別の世界のT細胞リンパ腫市場の成長機会
  • 地域別の世界のT細胞リンパ腫市場の成長機会
• 世界のT細胞リンパ腫市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のT細胞リンパ腫市場の能力拡大
  • 世界のT細胞リンパ腫市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Johnson & Johnson
• Novartis
• Bristol Myers Squibb Company
• Merck
• F. Hoffmann-La Roche

T-Cell Lymphoma Trends and Forecast

The future of the global T-cell lymphoma market looks promising with opportunities in the radiotherapy, chemotherapy, immunotherapy, and stem cell transplantation markets. The global T-cell lymphoma market is expected to reach an estimated $3.3 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are rising incidence of T-cell lymphomas globally, advances in technologies related to cancer treatment, and growing usage of immunotherapies, including car-t cell therapies and immune checkpoint inhibitors.

A more than 150-page report is developed to help in your business decisions.

T-Cell Lymphoma by Segment

The study includes a forecast for the global T-cell lymphoma by type, therapy, and region.

T-Cell Lymphoma Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Peripheral T-Cell Lymphoma
• Cutaneous T-Cell Lymphoma
• Anaplastic Large Cell Lymphoma
• Angio-Immuno-Blastic T-Cell Lymphoma

T-Cell Lymphoma Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

• Radiotherapy
• Chemotherapy
• Immunotherapy
• Stem Cell Transplantation
• Others

T-Cell Lymphoma Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of T-Cell Lymphoma Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies T-cell lymphoma companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the T-cell lymphoma companies profiled in this report include-

• Johnson & Johnson
• Novartis
• Bristol Myers Squibb Company
• Merck
• F. Hoffmann-La Roche

T-Cell Lymphoma Market Insights

Lucintel forecasts that peripheral T-cell lymphoma is expected to witness the highest growth over the forecast period because it is increasingly found in children and young adults, which is slow-growing type of lymphoma, but it can be difficult to treat.

North America will remain the largest region over the forecast period due to high T-cell lymphoma prevalence, existence of major industry participants, and rise in R&D activities.

Features of the Global T-Cell Lymphoma Market

Market Size Estimates: T-cell lymphoma market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: T-cell lymphoma market size by type, therapy, and region in terms of value ($B).

Regional Analysis: T-cell lymphoma market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, therapy, and regions for the T-cell lymphoma market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the T-cell lymphoma market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the T-cell lymphoma market size?

Answer: The global T-cell lymphoma market is expected to reach an estimated $3.3 billion by 2030.

Q2. What is the growth forecast for T-cell lymphoma market?

Answer: The global T-cell lymphoma market is expected to grow with a CAGR of 6.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the T-cell lymphoma market?

Answer: The major drivers for this market are rising incidence of T-cell lymphomas globally, advances in technologies related to cancer treatment, and growing usage of immunotherapies, including car-t cell therapies and immune checkpoint inhibitors.

Q4. What are the major segments for T-cell lymphoma market?

Answer: The future of the global T-cell lymphoma market looks promising with opportunities in the radiotherapy, chemotherapy, immunotherapy, and stem cell transplantation markets.

Q5. Who are the key T-cell lymphoma market companies?

Answer: Some of the key T-cell lymphoma companies are as follows:

• Johnson & Johnson
• Novartis
• Bristol Myers Squibb Company
• Merck
• F. Hoffmann-La Roche

Q6. Which T-cell lymphoma market segment will be the largest in future?

Answer: Lucintel forecasts that peripheral T-cell lymphoma is expected to witness the highest growth over the forecast period because it is increasingly found in children and young adults, which is slow-growing type of lymphoma, but it can be difficult to treat.

Q7. In T-cell lymphoma market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high T-cell lymphoma prevalence, existence of major industry participants, and rise in R&D activities.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the T-cell lymphoma market by type (peripheral T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, and angio-immuno-blastic T-cell lymphoma), therapy (radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global T-Cell Lymphoma Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global T-Cell Lymphoma Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global T-Cell Lymphoma Market by Type
  • 3.3.1: Peripheral T-cell Lymphoma
  • 3.3.2: Cutaneous T-cell Lymphoma
  • 3.3.3: Anaplastic Large Cell Lymphoma
  • 3.3.4: Angio-Immuno-blastic T-cell Lymphoma
• 3.4: Global T-Cell Lymphoma Market by Therapy
  • 3.4.1: Radiotherapy
  • 3.4.2: Chemotherapy
  • 3.4.3: Immunotherapy
  • 3.4.4: Stem Cell Transplantation
  • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global T-Cell Lymphoma Market by Region
• 4.2: North American T-Cell Lymphoma Market
  • 4.2.2: North American T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
• 4.3: European T-Cell Lymphoma Market
  • 4.3.1: European T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
  • 4.3.2: European T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
• 4.4: APAC T-Cell Lymphoma Market
  • 4.4.1: APAC T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
  • 4.4.2: APAC T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
• 4.5: ROW T-Cell Lymphoma Market
  • 4.5.1: ROW T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
  • 4.5.2: ROW T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global T-Cell Lymphoma Market by Type
  • 6.1.2: Growth Opportunities for the Global T-Cell Lymphoma Market by Therapy
  • 6.1.3: Growth Opportunities for the Global T-Cell Lymphoma Market by Region
• 6.2: Emerging Trends in the Global T-Cell Lymphoma Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global T-Cell Lymphoma Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global T-Cell Lymphoma Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Johnson & Johnson
• 7.2: Novartis
• 7.3: Bristol Myers Squibb Company
• 7.4: Merck
• 7.5: F. Hoffmann-La Roche